Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
ARTV
$4.95
$
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Next Earnings
2026-02-25
Beta
2.9463482
Average Volume
Market Cap
Last Dividend
CIK
0001817241
ISIN
US04317A1079
CUSIP
CEO
Fred Aslan
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
96
IPO Date
2024-07-19
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference | SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that Artiva management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026, at 1:10 p.m. EST, in Boston, MA. | GlobeNewsWire | 2026-02-25 08:00:00 |
| Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant | SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Thad Huston as Chief Financial Officer. Mr. Huston brings proven expertise in capital allocation, operational execution and global commercialization to support Artiva as it advances AlloNK in autoimmune diseases and continues building an organization positioned for long-term value creation. | GlobeNewsWire | 2026-02-24 08:00:00 |
| Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors | SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Elaine Sorg to its Board of Directors. Ms. Sorg brings more than 35 years of executive leadership and commercial experience in the biopharmaceutical industry to Artiva, including leading the commercialization of major immunology therapies such as HUMIRA® (adalimumab) and RINVOQ® (upadacitinib) for rheumatoid arthritis. | GlobeNewsWire | 2026-02-19 08:00:00 |
| Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Short Interest Down 28.5% in January | Artiva Biotherapeutics, Inc. (NASDAQ: ARTV - Get Free Report) saw a significant decrease in short interest during the month of January. As of January 30th, there was short interest totaling 203,792 shares, a decrease of 28.5% from the January 15th total of 284,944 shares. Currently, 1.1% of the company's shares are sold short. Based on an | Defense World | 2026-02-16 02:14:56 |
| Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $19.00 Average PT from Brokerages | Shares of Artiva Biotherapeutics, Inc. (NASDAQ: ARTV - Get Free Report) have received an average rating of "Moderate Buy" from the six brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating | Defense World | 2026-02-08 01:32:48 |
| Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) from February 4 – 7, 2026, in Salt Lake City, Utah highlighting the cost-effectiveness of AlloNK in a community rheumatology practice and continued durability of AlloNK in Non-Hodgkin Lymphoma (NHL). The following abstracts will be presented as poster presentations at the 2026 Tandem Meetings: Poster ID: 440 AB-101, an Off-the-Shelf NK Cell Therapy Administered in an Outpatient Community Rheumatology Practice, Is More Cost-Effective Than CAR-T Treatments for Rheumatologic Diseases Poster Session: Health Services and Barriers to Access Date / Time: Thursday, February 5, 2026, at 6:30 pm MST Author: Nicholas Veomett, Ph.D. | GlobeNewsWire | 2026-01-21 08:00:00 |
| Artiva Biotherapeutics: Upcoming Data Presentations May Bring Them Out Of Being Ignored | Artiva Biotherapeutics is working on NK cell-based immunotherapy to treat autoimmune disease. Their lead project is an unmodified, preserved NK product that seeks to address challenges posed for CAR T-cell therapies. Early trial data in B-cell lymphoma suggests activity, and ARTV is guiding a data readout in the near term for autoimmune disease. | Seeking Alpha | 2026-01-15 20:02:36 |
| Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Sees Significant Growth in Short Interest | Artiva Biotherapeutics, Inc. (NASDAQ: ARTV - Get Free Report) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 391,100 shares, an increase of 119.5% from the December 15th total of 178,188 shares. Approximately 2.0% of the shares of the stock are | Defense World | 2026-01-14 03:52:47 |
| Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $19.00 Consensus PT from Analysts | Artiva Biotherapeutics, Inc. (NASDAQ: ARTV - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six ratings firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to | Defense World | 2026-01-14 02:16:50 |
| Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines | /PRNewswire/ -- NanoSyrinx, a synthetic biology company developing Nanosyringes as a novel platform for targeted intracellular delivery of biologic | PRNewsWire | 2026-01-08 03:30:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 3 | 2026-02-24 | 2026-02-24 | View Filing |
| 8-K | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-19 | 2026-02-19 | View Filing |
| 3 | 2026-02-19 | 2026-02-19 | View Filing |
| 8-K | 2026-02-19 | 2026-02-19 | View Filing |
| 4 | 2026-02-18 | 2026-02-18 | View Filing |
| 4 | 2026-02-18 | 2026-02-18 | View Filing |
| 4 | 2026-02-18 | 2026-02-18 | View Filing |
| 4 | 2026-02-18 | 2026-02-18 | View Filing |
| 4 | 2026-02-18 | 2026-02-18 | View Filing |
| 4 | 2025-12-15 | 2025-12-15 | View Filing |
| 4 | 2025-12-12 | 2025-12-12 | View Filing |
| 4 | 2025-12-12 | 2025-12-12 | View Filing |
| 4 | 2025-12-12 | 2025-12-12 | View Filing |
| 4 | 2025-12-12 | 2025-12-12 | View Filing |
| 8-K | 2025-12-12 | 2025-12-12 | View Filing |
| 4 | 2025-11-17 | 2025-11-17 | View Filing |
| 4 | 2025-11-17 | 2025-11-17 | View Filing |
| 4 | 2025-11-17 | 2025-11-17 | View Filing |
| 4 | 2025-11-17 | 2025-11-17 | View Filing |
| 4 | 2025-11-17 | 2025-11-17 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 4 | 2025-10-17 | 2025-10-17 | View Filing |
| 4 | 2025-08-18 | 2025-08-18 | View Filing |
| 4 | 2025-08-18 | 2025-08-18 | View Filing |
| 4 | 2025-08-18 | 2025-08-18 | View Filing |
| 4 | 2025-08-18 | 2025-08-18 | View Filing |
| 4 | 2025-08-18 | 2025-08-18 | View Filing |
| EFFECT | 2025-08-18 | 2025-08-18 | View Filing |
| S-3 | 2025-08-06 | 2025-08-06 | View Filing |
| S-8 | 2025-08-06 | 2025-08-06 | View Filing |
| 10-Q | 2025-08-06 | 2025-08-06 | View Filing |
| 8-K | 2025-08-06 | 2025-08-06 | View Filing |
| SC 13G/A | 2025-07-16 | 2025-07-16 | View Filing |
| 4 | 2025-06-26 | 2025-06-26 | View Filing |
| 4 | 2025-06-26 | 2025-06-26 | View Filing |
| 4 | 2025-06-26 | 2025-06-26 | View Filing |
| 4 | 2025-06-26 | 2025-06-26 | View Filing |
| 4 | 2025-06-26 | 2025-06-26 | View Filing |
| 4 | 2025-06-26 | 2025-06-26 | View Filing |
| 4 | 2025-06-26 | 2025-06-26 | View Filing |
| 8-K | 2025-06-25 | 2025-06-25 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| 10-Q | 2025-05-08 | 2025-05-08 | View Filing |
| 8-K | 2025-05-08 | 2025-05-08 | View Filing |
| ARS | 2025-04-29 | 2025-04-29 | View Filing |
| DEFA14A | 2025-04-29 | 2025-04-29 | View Filing |
| DEF 14A | 2025-04-29 | 2025-04-29 | View Filing |
| 4 | 2025-04-25 | 2025-04-25 | View Filing |
| 3 | 2025-04-25 | 2025-04-25 | View Filing |
| SC 13G | 2025-04-23 | 2025-04-24 | View Filing |
| 10-K | 2025-03-24 | 2025-03-24 | View Filing |
| 8-K | 2025-03-24 | 2025-03-24 | View Filing |
| 4 | 2025-03-07 | 2025-03-07 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-01-29 | 2025-01-29 | View Filing |
| 3 | 2025-01-29 | 2025-01-29 | View Filing |
| 8-K | 2025-01-29 | 2025-01-29 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-11-12 | 2024-11-12 | View Filing |
| 4 | 2024-10-22 | 2024-10-23 | View Filing |
| 3 | 2024-10-22 | 2024-10-23 | View Filing |
| 8-K | 2024-10-22 | 2024-10-22 | View Filing |
| 4 | 2024-09-13 | 2024-09-13 | View Filing |
| 4 | 2024-09-13 | 2024-09-13 | View Filing |
| 4 | 2024-09-13 | 2024-09-13 | View Filing |
| 4 | 2024-09-13 | 2024-09-13 | View Filing |
| 4 | 2024-09-13 | 2024-09-13 | View Filing |
| SC 13D/A | 2024-09-03 | 2024-09-03 | View Filing |
| 10-Q | 2024-08-29 | 2024-08-29 | View Filing |
| 8-K | 2024-08-29 | 2024-08-29 | View Filing |
| SC 13G | 2024-08-01 | 2024-08-01 | View Filing |
| SC 13G | 2024-08-01 | 2024-08-01 | View Filing |
| SC 13G | 2024-08-01 | 2024-08-01 | View Filing |
| SC 13D | 2024-07-29 | 2024-07-29 | View Filing |
| SC 13D | 2024-07-29 | 2024-07-29 | View Filing |
| 4 | 2024-07-24 | 2024-07-24 | View Filing |
| 4 | 2024-07-24 | 2024-07-24 | View Filing |
| SEC STAFF LETTER | 2024-07-19 | 2024-07-23 | View Filing |
| 4 | 2024-07-22 | 2024-07-23 | View Filing |
| 4 | 2024-07-22 | 2024-07-23 | View Filing |
| 4 | 2024-07-22 | 2024-07-23 | View Filing |
| 4 | 2024-07-22 | 2024-07-23 | View Filing |
| 4 | 2024-07-22 | 2024-07-23 | View Filing |
| S-8 | 2024-07-22 | 2024-07-22 | View Filing |
| 8-K | 2024-07-22 | 2024-07-22 | View Filing |
| 424B4 | 2024-07-22 | 2024-07-19 | View Filing |
| EFFECT | 2024-07-18 | 2024-07-19 | View Filing |
| 3 | 2024-07-18 | 2024-07-19 | View Filing |
| 3 | 2024-07-18 | 2024-07-19 | View Filing |
| 3 | 2024-07-18 | 2024-07-19 | View Filing |
| 3 | 2024-07-18 | 2024-07-19 | View Filing |
| 3 | 2024-07-18 | 2024-07-19 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Larry Williams PercentR Strategy | 121.82% | 0.98 | 220 | 0.04 | 0.12 | 125.93 |
| Williams PercentR Strategy | 101.19% | 0.99 | 408 | 0.03 | 0.09 | 105.3 |
| Fractal Pattern | 80.06% | 0.97 | 84 | 0.04 | 0.1 | 84.18 |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxx |
| xxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | x | xxxx | xxxx |
| xxx | xxxxxxxx% | xxxx | xxx | x | x | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | x | x | xxxxx | xxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |